| Feature | Competitor (e.g., sotorasib) | MEYD‑873 | |---------|----------------------------|----------| | | KRAS‑G12C only | KRAS‑G12D + RAF‑dimer inhibition | | Resistance Profile | Frequently re‑activates via BRAF/CRAF dimerization | Dual‑lock blocks that route | | Safety | Grade ≥ 3 liver enzyme elevation in 12 % of pts | No ≥ Grade 3 liver events in pre‑clinical toxicology | | Oral Dosing | BID (twice daily) | QD (once daily) | | Companion Diagnostic | KRAS‑mut status only | KRAS‑G12D + RAF‑DimerScore™ (dual biomarker) |
Patients meeting both criteria are the ideal candidates for MEYD‑873 therapy. Our companion diagnostic is already CE‑IVD approved and will be launched concurrently with the drug. MEYD-873
| Parameter | Value | Interpretation | |-----------|-------|----------------| | | > 10 µM | Negligible cardiac effects | | Plasma protein binding | 18 % | High free fraction for CNS delivery | | Cmax (IV, 5 mg kg⁻¹) | 2.3 µM | Well below toxicity threshold | | LD 50 (mouse, oral) | > 250 mg kg⁻¹ | Wide safety margin | | Neurotoxicity (in vitro) | No observable loss of viability at 10 µM for 48 h | Compatible with chronic use | | Feature | Competitor (e
📅 [Date] 💡 Discover how MEYD‑873 can power your business: [URL] The future of [your field] is here, delivering
“🚀 Meet MEYD‑873! The future of [your field] is here, delivering [benefit] with style. Swipe up to discover more. #FutureTech #MEYD873”